Talaris Therapeutics, Inc. (TALS): Price and Financial Metrics


Talaris Therapeutics, Inc. (TALS): $7.37

0.27 (+3.80%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TALS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TALS Stock Price Chart Interactive Chart >

Price chart for TALS

TALS Price/Volume Stats

Current price $7.37 52-week high $19.82
Prev. close $7.10 52-week low $5.70
Day low $7.04 Volume 49,500
Day high $7.55 Avg. volume 46,603
50-day MA $8.12 Dividend yield N/A
200-day MA $11.68 Market Cap 305.52M

Talaris Therapeutics, Inc. (TALS) Company Bio


Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.


TALS Latest News Stream


Event/Time News Detail
Loading, please wait...

TALS Latest Social Stream


Loading social stream, please wait...

View Full TALS Social Stream

Latest TALS News From Around the Web

Below are the latest news stories about Talaris Therapeutics Inc that investors may wish to consider to help them evaluate TALS as an investment opportunity.

Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

BOSTON and LOUISVILLE, Ky., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 AM ET.

GlobeNewswire | February 11, 2022

We're Hopeful That Talaris Therapeutics (NASDAQ:TALS) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | February 8, 2022

Altium Wealth Management LLC Buys Vanguard FTSE Emerging Markets ETF, Invesco Variable Rate ...

Investment company Altium Wealth Management LLC (Current Portfolio) buys Vanguard FTSE Emerging Markets ETF, Invesco Variable Rate Preferred ETF, Charles Schwab Corp, Hartford Municipal Opportunities ETF, Talaris Therapeutics Inc, sells Banco Santander SA, Federal Realty Investment Trust, Sysco Corp, Rockwell Automation Inc, iShares MSCI EAFE Small-Cap ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Altium Wealth Management LLC.

Yahoo | January 31, 2022

Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON and LOUISVILLE, Ky., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 PM ET. A live webcast o

Yahoo | January 6, 2022

Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

BOSTON and LOUISVILLE, Ky., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022. A webcast of the pre-recorded pre

Yahoo | January 4, 2022

Read More 'TALS' Stories Here

TALS Price Returns

1-mo 0.14%
3-mo N/A
6-mo -39.69%
1-year -44.38%
3-year N/A
5-year N/A
YTD -51.80%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.703 seconds.